    Daphne Quimi | Amicus Therapeutics Inc | ZoomInfo.com

Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version















FOLD Daphne E. Quimi Insider Trades for Amicus Therapeutics Inc.


































Bulletin

Merck profit and sales top expectations amid big jump in Keytruda sales »
        




Investor Alert







New York Markets Open in:



Market Snapshot
Analyst Ratings


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Amicus Therapeutics Inc.

                  NASDAQ: FOLD
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Amicus Therapeutics Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 27, 2017, 4:58 p.m.


FOLD

/quotes/zigman/102267/composite


$
13.22




Change

-0.0016
-0.01%

Volume
Volume 29,073
Quotes are delayed by 20 min








/quotes/zigman/102267/composite
Previous close

$
			13.70
		


$
				13.22
			
Change

-0.48
-3.50%





Day low
Day high
$12.70
$13.90










52 week low
52 week high

            $4.41
        

            $14.05
        


















Insider Activity


Individual




Daphne E. Quimi



Ms. Daphne E. Quimi is Senior Vice President-Finance & Administration at Amicus Therapeutics, Inc., a Member at Institute of Management Accountants, Inc. and a Member at The American Institute of Certified Public Accountants. She received her undergraduate degree from Monmouth University and an MBA from New York University.



Transactions


Date
Shares
Transaction
Value





01/03/2017
30,487


 
Award at $0 per share.


0


11/09/2016
2,858


 
Disposition at $8 per share.


22,864


11/09/2016
2,858


 
Derivative/Non-derivative trans. at $8 per share.


22,864


11/09/2016
5,688


 
Disposition at $8 per share.


45,504


06/15/2016
8,500


 
Award at $0 per share.


0


01/04/2016
9,311


 
Derivative/Non-derivative trans. at $9.03 per share.


84,079


01/04/2016
25,000


 
Derivative/Non-derivative trans. at $0 per share.


0


10/01/2015
11,250


 
Disposition at $13.13 per share.


147,713


10/01/2015
11,250


 
Derivative/Non-derivative trans. at $13.13 per share.


147,712


09/14/2015
2,500


 
Disposition at $18.08 per share.


45,200


07/01/2015
2,600


 
Disposition at $13.98 per share.


36,348


07/01/2015
2,600


 
Derivative/Non-derivative trans. at $13.98 per share.


36,348


05/11/2015
7,500


 
Disposition at $10.84 per share.


81,300


05/08/2015
9,312


 
Derivative/Non-derivative trans. at $10.8 per share.


100,570


05/08/2015
25,000


 
Derivative/Non-derivative trans. at $0 per share.


0


11/25/2014
3,500


 
Disposition at $8 per share.


28,000


11/25/2014
3,500


 
Acquisition at $8 per share.


28,000


10/03/2014
6,812


 
Disposition at $7 per share.


47,684


10/03/2014
6,812


 
Acquisition at $7 per share.


47,684


09/29/2014
10,738


 
Disposition at $6.1 per share.


65,502


09/29/2014
10,738


 
Acquisition at $6.1 per share.


65,501


04/10/2014
50,000


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. John Francis Crowley 
Chairman & Chief Executive Officer




Mr. Bradley L. Campbell 
President & Chief Operating Officer




Mr. William D. Baird 
Chief Financial Officer




Dr. Jay A. Barth 
Chief Medical Officer




Dr. Hung  Do 
Chief Scientific Officer




Dr. Enrique  Dilone 
Senior Vice President-Technical Operations




Ms. Daphne E. Quimi 
Senior Vice President-Finance & Administration




Mr. Dipal  Doshi 
Chief Business Officer




Mr. Jeffrey P. Castelli 
SVP-Program Management & Portfolio Planning




Ms. Jayne C. Gershkowitz 
Chief Patient Advocate




Dr. Kenneth J. Valenzano 
Senior Vice President-Preclinical Research




Mr. Patrik S. Florencio 
Chief Compliance Officer




Mr. Willem W. van Weperen 
Regional Vice President




Mr. David  Allsopp 
Senior Vice President-International




Mr. Mark  Baldry 
Vice President-Global Marketing




Ms. Sara  Pellegrino 
Head-Investor & Media Relations




Mr. Kurt J. W. Andrews 
Senior Vice President-Human Resources




Ms. Ellen Stacy Rosenberg 
Secretary & General Counsel




Dr. Andrew E. Mulberg 
Vice President-Regulatory Strategy




Mr. John R. Kirk 
Vice President-Regulatory Affairs




Mr. Craig A. Wheeler 
Independent Director




Mr. Glenn P. Sblendorio 
Independent Director




Mr. Donald J. Hayden 
Lead Independent Director




Mr. Robert A. Essner 
Independent Director




Dr. Ted W. Love 
Independent Director




Mr. Michael G. Raab 
Independent Director




Ms. Margaret G. McGlynn 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




7:26 AM EDT
July 28, 2017


/marketstate/country/us
New York

	Pre


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
7:20aCan Snap fall even more as lockups expire?
7:19aChip stocks are cool again, but reality is here
7:19aWhere to get Chipotle queso: check out this interactive map
7:19aAaron's acquires its largest franchisee in all-cash deal
7:18aExpedia stock price target raised to $173 from $158 at Piper Jaffray
7:17aA provocative new analysis suggests you don’t have to take all your antibiotics after all
7:17aA case for buying the freakin’ dip with Amazon, as the Mooch might now say
7:17aPriceline stock price target raised to $2,150 from $1,900 at Piper Jaffray
7:15aSJW Group upgraded to buy from neutral at Janney
7:15aVF Corp. stock price target raised to $70 from $53 at Susquehanna Financial
7:15aDollar spins wheels ahead of GDP report expected to show faster clip of growth
7:14aVF Corp. upgraded to positive from neutral at Susquehanna Financial
7:13aTeradyne upgraded to overweight from sector weight at KeyBanc Capital
7:13aLogMeIn upgraded to overweight from sector weight at KeyBanc Capital
7:11aTwitter stock price target raised to $14 from $13 at RBC Capital
7:08aCoca-Cola Zero Sugar sparks analyst optimism, but other factors could stifle growth
7:06aIntel stock price target raised to $39 from $38 at SunTrust RH
7:06aMasterCard stock price target raised to $145 from $135 at SunTrust RH
7:05aCharter Communications stock price target raised to $400 from $380 at SunTrust RH
7:04aWhy the GDP report may show U.S. economy growing twice as fast
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,796.55

+85.54
+0.39%





nasdaq

/quotes/zigman/12633936/realtime
6,382.19

-40.56
-0.63%





s&p 500

/quotes/zigman/3870025/realtime
2,475.42

-2.41
-0.10%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15























































Reuters.com


























































X



Edition:

United States


















Africa
América Latina


عربي
Argentina


Brasil
Canada


中国
Deutschland


España
France


India
Italia


日本
México


РОССИЯ
United Kingdom

United States
















People: Amicus Therapeutics Inc (FOLD.O)





Related Topics: 
StocksStock ScreenerHealthcarePharmaceuticals












                
                        Overview
                    



                
                        News
                    



                
                        Key Developments
                    



                
                        People
                    



                
                        Charts
                    



                
                        Financials
                    



                
                        Analysts
                    



                    
                            Research
                        



                    
                            Pulse
                        










				FOLD.O on Consolidated Issue listed on NASDAQ Global Market


				13.22USD
27 Jul 2017





				    Change	(% chg)


		    
						    --


					            (--)
					        






Prev Close

$13.22


Open

--




Day's High

--


Day's Low

--




Volume

--


Avg. Vol

3,121,326




52-wk High

$14.05


52-wk Low

$4.41










	Quimi, Daphne 





	Ms. Daphne E. Quimi serves as Senior Vice President - Finance and Administration, Corporate Controller of Amicus Therapeutics Inc. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at Johnson & Johnson. Ms. Quimi brings extensive experience in public accounting and financial reporting. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A. from the Stern School of Business of New York University. She is a certified public accountant in New Jersey and a member of the American Institute of Certified Public Accountants and the Institute of Management Accountants.



Basic Compensation




Total Annual Compensation, USD
247,397


Restricted Stock Awards, USD
--


Long-Term Incentive Plans, USD
--


All Other, USD
78,002


Fiscal Year Total, USD
325,399








Options Compensation




 
Quantity
Market Value


Exercisable
--
--


Unexercisable
--
--


Exercised
--
--














					Basic Compensation






Name
Fiscal Year Total




							John Crowley

4,199,370




							Bradley Campbell

1,770,170




							William Baird

1,467,060




							Daphne Quimi

325,399




							Kurt Andrews

--




							Hung Do

1,271,930



As Of 
30 Dec 2016

» View All Officers
















Related Topics: 
StocksStock ScreenerHealthcarePharmaceuticals





























Daphne E. Quimi - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Daphne E. Quimi
Corporate Controller at Amicus Therapeutics, Inc.


View Full Profile
Are you Daphne E. Quimi? Claim your profile


 


Sign up for Equilar Atlas and view Daphne E. Quimi's full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Daphne E. Quimi's  network and community.
												FOLLOW changes in Daphne E. Quimi's employment and money-in-motion.
												CONNECT with Daphne E. Quimi through your network of contacts.
												








Daphne E. Quimi's Executive Work History


Current


Corporate Controller, 
Amicus Therapeutics, Inc.


Past
To view Daphne E. Quimi's complete executive work history, sign up now
Age
51

 
 


Daphne E. Quimi's Biography




			Daphne Quimi, 47, has served as Corporate Controller since January 2010 and, prior thereto, as Director of Accounting Policy and External Reporting since September 2007. From October 2005 to September 2007, Ms. Quimi worked at Bristol-Myers Squibb Company where she served as Director of Consolidations and External Reporting. Ms. Quimi is a certified public accountant in New Jersey and a member of the American Institute of Certified Public Accountants and the Institute of Management Accountants. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A from the Stern School of Business of New York University.
		
Source: Amicus Therapeutics, Inc. on 04/26/2013
		
	

 






Sign up for Equilar Atlas and view Daphne E. Quimi's full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Daphne E. Quimi. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Daphne E. Quimi's  network and community.
												FOLLOW changes in Daphne E. Quimi's employment and money-in-motion.
												CONNECT with Daphne E. Quimi through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Daphne E. Quimi


















Daphne E. Quimi's Connections (37)





Sign up now to view Daphne E. Quimi's 37 connections »









S. Nicole O. Schaeffer
Senior Vice President, Human Resources and Corporate Services, Insmed Incorporated









David J. Lockhart
Former Chief Scientific Officer, Amicus Therapeutics, Inc.









Ted W. Love
Dir., President and Chief Executive Officer, Global Blood Therapeutics, Inc.









Joan C. Winterbottom
Former Vice President and Chief Human Resources Officer, Argos Therapeutics, Inc.









William D. Baird
Chief Financial Officer, Amicus Therapeutics, Inc.









Margaret G. McGlynn
Board Member, Air Products









John F. Crowley
Chairman of the Board and Chief Executive Officer, Amicus Therapeutics, Inc.









Kenneth W. Peist
Former Vice President, Legal and Intellectual Property, Amicus Therapeutics, Inc.









Craig A. Wheeler
Dir., President and Chief Executive Officer, Momenta Pharmaceuticals, Inc.









M. James Barrett
Chairman of the Board, Proteostasis Therapeutics, Inc.








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.









Elon R. Musk
CEO and Chairman, Tesla









Michael C. Montgomery
Board Member, NMI Holdings, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

ï¿½ 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993













﻿







Daphne Quimi Unloaded 11250 shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in an Insider Trade – Octafinance
























































 








Friday, 28 July 2017

























 

Menu



Featured News


						2 years ago - Alphabet Inc (NASDAQ:GOOGL) Tests Its Ad Technology On Billboards To Cushion Itself Against Ad Blocks


						2 years ago - China Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking Crisis


						2 years ago - Marc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and Gold


						2 years ago - Carl Icahn Criticizes the Fed. Feels Bad For Investors Buying Junk Bonds


						2 years ago - John Burbank: European QE Can’t Save The Markets Same As the U.S. Quantitative Easing. Everything Will Be Liquidated










Daphne Quimi Unloaded 11250 shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in an Insider Trade


10/06/2015  by OctaStaff 
			in Insider News, Momentum Equities 












Share with your friendsYour NameYour EmailRecipient EmailEnter a MessageI read this article and found it very interesting, thought it might be interesting for you. The article is called Daphne Quimi Unloaded 11250 shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in an Insider Trade and is was published by Octafinance.com at http://www.octafinance.com/daphne-quimi-unloaded-11250-shares-of-amicus-therapeutics-inc-nasdaqfold-in-an-insider-trade/216145/.CaptchaSubmit
Daphne Quimi Insider Sell Transaction
 Daphne Quimi is the Vice President Finance of Amicus Therapeutics, Inc. (NASDAQ:FOLD)  13.22 -0.48 -3.50%. She a few days ago sold 11,250 shares in the public firm with the transaction value totalling exactly $147,761 U.S. Dollars. This is based on the transaction provided price of $13.1 per share. This is not her first insider trade, in the last 30 days, she unloaded another 2,500 shares worth $45,200 USD. Currently, Mr. Daphne, has 5,688 shares, which accounts for 0.00% of the Company’s market capitalization.
Amicus Therapeutics Inc Stock Rating, Sentiment and Fundamentals
 It is difficult to make conclusions about Amicus Therapeutics Inc’s future just from Daphne Quimi’s sale because in this filing, the insider also revealed option transactions. In the form, it was reported that Daphne exercised options for 11,250 shares with average price 13.1, worth 147,761. The five leading equity analysts that cover the corporation financial position forecast $-1.15 earnings-per-share for 2015 which gives Amicus Therapeutics Inc Price/Earnings ratio of NaN. 






Rating & SentimentPsychSignal Social:SELLAnalysts Rating:BUYHedge Funds Sentiment:BUY




Stock FundamentalsEarnings + FCF Trend:SELLSector/Industry Macro:BULLISHValuation Models:-


 


Technical AnalysisST Trend:DOWNMT Trend:DOWNLT Trend:DOWN




OctaFinance Rating*:SELL


* Read How Our Stock Ratings System Works








 Chart analysis shows Amicus Therapeutics Inc’s share price dived 12.52% in the last 200 days. And this downward trend looks set to continue. We too rate the -listed company’s stock a sell mainly because of our equities trend-following model which is displayed below.
Price Chart of Amicus Therapeutics NASDAQ:FOLD Stock
 
Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations
 Legendary stock traders, who also include Paul Tudor Jones, once shared that the highest returns are made when technical & fundamental analysis are combined. 
Hedge Funds Ownership
 In the last quarter 136 hedge funds and institutional investors owned Amicus Therapeutics Inc. The institutional ownership of the firm in Q2 2015 is high, at 94.93% of the shares outstanding. They increased by 32.00 million the total shares they hold. As of that quarter these investment managers owned 112.61 million shares. A total of 42 funds opened new positions in Amicus Therapeutics Inc and 53 increased their holdings. There were 25 funds that closed their positions and 32 that reduced them. 
 As published by SEC’s 13F filings, the firm is in Top 10 stock holdings of six funds. Some of them are: Longwood Capital Partners Llc, Perceptive Advisors Llc, Venbio Select Advisor Llc, Redmile Group Llc, Eam Investors Llc, Apis Capital Advisors Llc.

 Longwood Capital Partners Llc had the greatest investment with ownership of 1.78 million shares as of Q2 2015 for 15.53% of the fund’s portfolio. Joseph Edelman’s Perceptive Advisors Llc is another positive institutional investor owning 14.44 million shares of the company or 12.30% of their stocks portfolio. The stock is also 9.79% of the fund’s AUM. The California-based fund Venbio Select Advisor Llc have 17.89% of their stock portfolio invested in the stock for 4.59 million shares. Further, Jeremy Green’s Redmile Group Llc disclosed it had acquired a stake worth 7.30% of the fund’s stock portfolio in the company. The California-based fund Eam Investors Llc was also a notable believer in the firm, possessing 514,470 shares. Amicus Therapeutics Inc is 0.85% of the fund’s stock portfolio.
Amicus Therapeutics NASDAQ:FOLD Company Profile
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.
Company Website: Amicus Therapeutics
 Amicus Therapeutics Inc was founded in Delaware on 2002-02-04. The firm has 97 employees. As of writing its market capitalization is: $812.53 million and it has 127.16 million shares outstanding. At the moment there are 97.92% shareholders and the institutional ownership is 97.92%. The stock closed at $6.85 yesterday and it had average 2 days volume of 6173930 shares. It is up from the 30 days average shares volume of 1127307. Amicus Therapeutics Inc has a one year low of $5.13 and a 250 days high of $18.82. The current price is below the 200 days SMA.
* The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17 – 2014.
* This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.59 to $13.73. The reporting person undertakes to provide – upon request – by the staff of the Securities and Exchange Commission – the issuer – or a security holder of the issuer – full information regarding the number of shares purchased at each separate price.
* This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.59 to $13.73. The reporting person undertakes to provide – upon request – by the staff of the Securities and Exchange Commission – the issuer – or a security holder of the issuer – full information regarding the number of shares sold at each separate price.

Amicus Therapeutics - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.



 



 
Tagged: Amicus Therapeutics - (NASDAQ:FOLD)Daphne Quimi



Hanesbrands Inc (NYSE:HBI) Hedge Funds Sentiment Kenneth Peist, Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s insider Sold 10,000 Shares 



 





Amicus Therapeutics - Get News & Ratings Daily
    Enter your email address below to get the latest news and analysts' ratings for Amicus Therapeutics with our FREE daily email newsletter:



 



Hedge Fund NewsTop 10 CITADEL ADVISORS 13F Holdings in Q3 2015DF DENT & CO INC Just Released Its Q3 2015 Stock PositionsMAVERICK CAPITAL Top 10 Holdings in Q3 2015Analyzing Ken Griffins CITADEL ADVISORS Stock Holdings in Q3 2015LONE PINE CAPITAL Top 10 13F Positions in Q3 2015Guru NewsFelix Zulauf Sees a Stock Market Correction Coming. This Rally S&P 500 (INDEXSP:.INX) Will Be Short-LivedMarc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and GoldJim Grant: The Next Thing Might Be Helicopter Money. What to Buy and Where He Sees Investment OpportunitiesKyle Bass Bearish on Emerging Markets for at least 2 More Years. Looking to Short CurrenciesDavid Tepper Gets Defensive. Is it Time to Get Out of The Stock Market?


Macro NewsChina Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking CrisisAre US – Russian Relations A Zero-Sum Game?US and Russia have launched direct talks on the conflict in SyriaYuan Drops as PBOC Cuts Reference Rate by Most Since DevaluationCould the market crash like 1987?—put volume spike argues low is nearCTAs NewsRed Rock Just Published Report About The Trend Following Landscape & How CTAs’ Performance Must Be AnalyzedHow to Implement Dual Momentum for non-US InvestorsDo Commodity Trading Advisors (CTAs) Really Provide Crisis Alpha, Equity Hedge and Are Long Volatility?
























Daphne E. Quimi - Senior Vice President, Finance & Corporate Controller at Amicus Therapeutics, Inc.



























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology








            You have  
            
9 free profiles

              left this month   
			      

                Start Your Free Trial ➤
              








            Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there?
            

                View on RelSci Pro ➤
              




























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink





Daphne E. Quimi
Senior Vice President, Finance & Corporate Controller at Amicus Therapeutics, Inc.



Overview
Relationships Paths
Education Memberships Career History Public Holdings Transactions Awards & Honors 


Daphne E. Quimi
Senior Vice President, Finance & Corporate Controller at Amicus Therapeutics, Inc.



 Overview



Age



51
                                  (Born 1966)
                                              




Awards



1





Number of Relationships



                This person is connected to 842 people.
              






 Relationships
              See Details




John F. Crowley

Chief Executive Officer at Amicus Therapeutics, Inc.




Donald J. Hayden, Jr.

Senior Vice President at E. R. Squibb & Sons Inter-American Corp.





Geoffrey P. Gilmore

General Counsel at Agile Therapeutics, Inc.




Bradley L. Campbell

Former President & Chief Operating Officer at Amicus Therapeutics, Inc.





Matthew R. Patterson

Co-Founder at Audentes Therapeutics, Inc.




Enrique Dilone

Senior Vice President, Technical Operations at Amicus Therapeutics, Inc.





Jayne C. Gershkowitz

Former Senior Vice President, Patient & Professional Advocacy & Public Policy at Amicus Therapeutics, Inc.




Jeffrey P. Castelli

Senior Vice President-Program Management & Portfolio Planning at Amicus Therapeutics, Inc.





Jayne Gerskowitz

Senior Vice President, Patient & Professional Advocacy & Public Policy at Amicus Therapeutics, Inc.




William D. Baird III

Former Chief Financial Officer & Secretary at Amicus Therapeutics, Inc.







See 832 more listings with RelSci Professional.

Start My Free Trial ➤








See 832 More 


 


 Paths to Daphne E. Quimi



            Daphne E. Quimi          




 You



 Connections via Relationship Science



 Daphne E. Quimi






Sync your contacts to see how you can connect with Daphne E. Quimi.

Start My Free Trial ➤








See  More 


 


 Educational Background



B.S in Accountancy 


Monmouth University

                  Monmouth University is a leading private institution that offers a comprehensive array of undergraduate and graduate degree programs. The University provides students with a highly personalized education that builds the knowledge and confidence of tomorrow's leaders. Located in West Long Branch, New Jersey, Monmouth University's magnificent and historic campus is approximately one hour from both New York City and Philadelphia and is within walking distance of the beaches of the Atlantic Ocean. Learn more about what makes Monmouth a unique, full-spectrum institution of higher education.                




MBA 


New York University - Leonard N. Stern School of Business

                  Since its inception in 1900, New York University Stern School of Business has been in and of New York City.

Founded as the School of Commerce, Finance, and Accounting, the School initially offered training to students for careers in commerce in the burgeoning financial markets of New York City. 

Today, located in the heart of Greenwich Village with a campus in Westchester, Stern is one of the nation’s premier management education schools and research centers with a broad portfolio of academic programs at the graduate and undergraduate levels. With its global partnerships and engagement in NYU’s global network university, today NYU Stern is not only in and of the city, but also in and of the world.                





 Memberships



Member

                  Current                


American Institute of Certified Public Accountants

                  The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY.                




Member

                  Current                


Institute of Management Accountants

                  TO PROVIDE A FORUM FOR RESEARCH, PRACTICE DEVELOPMENT, EDUCATION, KNOWLEDGE SHARING, AND THE ADVOCACY OF THE HIGHEST ETHICAL AND BEST BUSINESS PRACTICES IN MANAGEMENT ACCOUNTING AND FINANCE.                





 Career History



Senior Vice President, Finance & Corporate Controller

                                    2005 - Current                


Amicus Therapeutics, Inc.


                  Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.                




Director-Consolidations & External Reporting

                                    2005 - 2007                


Bristol-Myers Squibb Company


                  Bristol-Myers Squibb Company

Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.                





 Public Holdings






Restricted data only for RelSci Professional users.

Start My Free Trial ➤








See  More 


 


 Transactions



 Details Hidden



                  Amicus Therapeutics, Inc. raised money in a private placement transaction                                  




 Details Hidden



                  Amicus Therapeutics, Inc. raised money in a private placement transaction                                  




 Details Hidden



                  Amicus Therapeutics, Inc. raised money in a private placement transaction                                  




 Details Hidden



                  Amicus Therapeutics, Inc. raised money in a private placement transaction                                  





 Awards & Honors




                  Professional Certification                




CPA (Certified Public Accountant)

                                    Sponsored by
                  American Institute of Certified Public Accountants






 Other Affiliations




              Daphne E. Quimi is affiliated with
                            Amicus Therapeutics, Inc., Bristol-Myers Squibb Company.
            





You've reached your 10 free profiles limit this month.
Upgrade to RelSci Pro today to enjoy unlimited article views and much more!

Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.












Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤













